ストックスクリーナーアプリを入手
26.48
7.61%
-2.18
アフターアワーズ：
26.05
-0.43
-1.62%
前日終値:
$28.66
開ける：
$29.14
24時間の取引高:
1.75M
Relative Volume:
1.90
時価総額：
$1.59B
収益：
$439.00K
当期純損益:
$-105.64M
株価収益率:
-14.71
EPS:
-1.8
ネットキャッシュフロー:
$-60.70M
1週間 パフォーマンス:
-7.77%
1か月 パフォーマンス:
+16.70%
6か月 パフォーマンス:
+3.04%
1年 パフォーマンス:
-51.15%
1日の値動き範囲:
$24.91
$29.14
1週間の範囲:
$24.91
$29.21
52週間の値動き範囲:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
26.48 | 1.72B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-10 | 開始されました | Stifel | Buy |
| 2025-09-10 | 開始されました | Truist | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-07-11 | 開始されました | Raymond James | Outperform |
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Janux Therapeutics price target raised to $46 from $45 at Stifel - TipRanks
JANX December 2026 Options Begin Trading - Nasdaq
Why Janux Therapeutics Inc. stock remains undervaluedJuly 2025 Breakouts & Expert-Curated Trade Recommendations - newser.com
Janux Therapeutics price target raised to $48 from $47 at Barclays - TipRanks
Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential - TipRanks
Janux Therapeutics Reports Strong Financial Position Amid Clinical Advancements - TipRanks
Janux Therapeutics Keeps Spending Up As Losses Narrow - Finimize
The Technical Signals Behind (JANX) That Institutions Follow - news.stocktradersdaily.com
Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments - TipRanks
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - BioSpace
Janux Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Promising Pipeline and Strategic Developments Justify Buy Rating for Janux Therapeutics Inc. - TipRanks
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q3 Revenue $10.0M, vs. FactSet Est of $2.9M - MarketScreener
Janux Therapeutics Q3 net loss narrows, R&D expenses rise - TradingView
Relative strength of Janux Therapeutics Inc. in sector analysisJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Will Janux Therapeutics Inc. price bounce be sustainableRisk Management & Expert Approved Momentum Trade Ideas - newser.com
Is Janux Therapeutics Inc. stock a safe buy before earningsWeekly Investment Report & Technical Confirmation Alerts - newser.com
Can Janux Therapeutics Inc. stock surprise with earnings upsideWeekly Market Outlook & Daily Price Action Insights - newser.com
How Janux Therapeutics Inc. stock benefits from strong dollar2025 Performance Recap & Fast Moving Stock Trade Plans - fcp.pa.gov.br
Using fundamentals and technicals on Janux Therapeutics Inc.Quarterly Earnings Summary & Weekly Momentum Stock Picks - newser.com
Is Janux Therapeutics Inc. stock attractive for income investorsJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
Volume spikes in Janux Therapeutics Inc. stock – what they meanJuly 2025 Technicals & Fast Moving Trade Plans - newser.com
Janux Therapeutics, Inc. (JANX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Is Restile Ceramics Limited Stock Discounted Enough After Recent DeclinesRSI Overbought/Oversold & Fast Profit Stock Ideas - earlytimes.in
Janux Therapeutics, Inc. (JANX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
What analysts say about Janux Therapeutics Inc stockTechnology Stock Trends & Turn Data into Profits With Our Strategies - earlytimes.in
AlphaQuest LLC Has $224,000 Stock Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 16,665 Shares of Stock - MarketBeat
Janux Therapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Exit strategy if you’re trapped in Janux Therapeutics Inc.Quarterly Market Review & Precise Trade Entry Recommendations - newser.com
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
Janux therapeutics CBO Meyer sells $500k in shares By Investing.com - Investing.com Canada
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
Janux Therapeutics Inc (JANX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
Oct 28 '25 |
Sale |
30.06 |
16,665 |
500,987 |
82,139 |
5.44%
0.70%
大文字化:
|
ボリューム (24 時間):